Pharmaceutical

EMA accepts for review Iveric Bio’s MAA for geographic atrophy therapy

Astellas Pharma has announced that EMA has accepted the MAA from its subsidiary Iveric Bio for the review of ACP to treat GA.

Aug 18, 2023 - 20:00
EMA accepts for review Iveric Bio’s MAA for geographic atrophy therapy
Astellas Pharma has announced that EMA has accepted the MAA from its subsidiary Iveric Bio for the review of ACP to treat GA.
Read the original article

Tags:

Previous Article

How competitive intelligence can give pharma companies an edge

Next Article

Nuvectis receives orphan drug designation for cholangiocarcinoma therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos’ turnaround

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos...

May 19, 2023

Does the hype around generative AI reflect its technology progress?

Does the hype around generative AI reflect its technolo...

Jul 5, 2023

J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC

J&Js Rybrevant plus Lazcluze combination gets FDA appro...

Aug 21, 2024